Melanoma, skin, Phase II

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high risk of recurrence.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Thuy Tran

thuy.tran@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Thuy Tran, MD, PhD
Assistant Professor of Medicine (Medical Oncology)

Sub-Investigators

Last Updated
04/11/2024
Study HIC
#2000025461